HY-109036 Search Results


sb9200  (MedChemExpress)
91
MedChemExpress sb9200
Sb9200, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sb9200/product/MedChemExpress
Average 91 stars, based on 1 article reviews
sb9200 - by Bioz Stars, 2026-02
91/100 stars
  Buy from Supplier
mavacamten  (MedChemExpress)
94
MedChemExpress mavacamten
Mavacamten, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mavacamten/product/MedChemExpress
Average 94 stars, based on 1 article reviews
mavacamten - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
dorzagliatin  (MedChemExpress)
94
MedChemExpress dorzagliatin
Mature 1420RH SC-islets respond to <t>dorzagliatin.</t> For testing the effect of dorzagliatin, S7W2 IS1 SC-islets ( a , b , d , e ) and IS2 SC-islets ( c , f ) were used. SC-islets were perifused with KRB containing 2 mmol/l glucose (2G, minutes 1–14) followed by 11 mmol/l glucose (11G) or 20 mmol/l glucose (20G, minutes 15–44) with or without 25 µmol/l dorzagliatin (DZG). The flowthrough was assessed for insulin secretion every minute. ( a ) Insulin secretory response (SI) from S7W2 IS1 heterozygous 1420RH SC-islets (differentiations 4–6) when treated with 11G glucose in the presence (dashed blue line) or absence (solid blue line) of DZG. The response from normal SC-islets (1420RR, green line) in the absence of DZG is shown as a reference. 1420RR, n =3; 1420RH, n =3. Data are presented as mean ± SEM. ( b , c ) Insulin secretory response from S7W2 IS1 ( b ) and IS2 ( c ) heterozygous 1420RH and homozygous 1420HH SC-islets when treated with 20G glucose in the presence (dashed blue line, 1420RH; dashed red line, 1420HH) or absence (solid blue line, 1420RH; solid red line, 1420HH) of DZG. The response from normal SC-islets (1420RR, green line) in the absence of DZG is shown as a reference. IS1 (differentiations 3–6): 1420RR, n =5; 1420RH, n =4; 1420HH, n =3. IS2 (differentiation 6 and 7): 1420RR, n =2; 1420RH, n =2; 1420HH, n =2. Data are presented as mean ± SEM. ( d ) First-phase peak, first-phase (minutes 15–22) and second-phase (minutes 23–44) SI during d-GSIS using S7W2 IS1 heterozygous 1420RH SC-islets ( n =3) challenged with 11G in the presence (light blue bar) or absence (blue bar) of DZG. The SI of normal SC-islets (1420RR, n =3, green bar) in the absence of DZG is shown as a reference. Data are presented as mean ± SD. ( e , f ) First-phase peak, first-phase (minutes 15–22) and second-phase (minutes 23–44) SI during d-GSIS using S7W2 IS1 ( e ) and IS2 ( f ) heterozygous 1420RH and homozygous 1420HH SC-islets challenged with 20G in the presence (light blue bars, 1420RH; light red bars, 1420HH) or absence (blue bars, 1420RH; red bars, 1420HH) of DZG. The SI of normal SC-islets (1420RR, green bars) in the absence of DZG is shown as a reference. IS1 (differentiations 3–6): 1420RR, n =5; 1420RH, n =4; 1420HH, n =3. IS2 (differentiation 6 and 7): 1420RR, n =2; 1420RH, n =2; 1420HH, n =2. Data are presented as mean ± SD. * p <0.05
Dorzagliatin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dorzagliatin/product/MedChemExpress
Average 94 stars, based on 1 article reviews
dorzagliatin - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
praliciguat  (MedChemExpress)
94
MedChemExpress praliciguat
Mature 1420RH SC-islets respond to <t>dorzagliatin.</t> For testing the effect of dorzagliatin, S7W2 IS1 SC-islets ( a , b , d , e ) and IS2 SC-islets ( c , f ) were used. SC-islets were perifused with KRB containing 2 mmol/l glucose (2G, minutes 1–14) followed by 11 mmol/l glucose (11G) or 20 mmol/l glucose (20G, minutes 15–44) with or without 25 µmol/l dorzagliatin (DZG). The flowthrough was assessed for insulin secretion every minute. ( a ) Insulin secretory response (SI) from S7W2 IS1 heterozygous 1420RH SC-islets (differentiations 4–6) when treated with 11G glucose in the presence (dashed blue line) or absence (solid blue line) of DZG. The response from normal SC-islets (1420RR, green line) in the absence of DZG is shown as a reference. 1420RR, n =3; 1420RH, n =3. Data are presented as mean ± SEM. ( b , c ) Insulin secretory response from S7W2 IS1 ( b ) and IS2 ( c ) heterozygous 1420RH and homozygous 1420HH SC-islets when treated with 20G glucose in the presence (dashed blue line, 1420RH; dashed red line, 1420HH) or absence (solid blue line, 1420RH; solid red line, 1420HH) of DZG. The response from normal SC-islets (1420RR, green line) in the absence of DZG is shown as a reference. IS1 (differentiations 3–6): 1420RR, n =5; 1420RH, n =4; 1420HH, n =3. IS2 (differentiation 6 and 7): 1420RR, n =2; 1420RH, n =2; 1420HH, n =2. Data are presented as mean ± SEM. ( d ) First-phase peak, first-phase (minutes 15–22) and second-phase (minutes 23–44) SI during d-GSIS using S7W2 IS1 heterozygous 1420RH SC-islets ( n =3) challenged with 11G in the presence (light blue bar) or absence (blue bar) of DZG. The SI of normal SC-islets (1420RR, n =3, green bar) in the absence of DZG is shown as a reference. Data are presented as mean ± SD. ( e , f ) First-phase peak, first-phase (minutes 15–22) and second-phase (minutes 23–44) SI during d-GSIS using S7W2 IS1 ( e ) and IS2 ( f ) heterozygous 1420RH and homozygous 1420HH SC-islets challenged with 20G in the presence (light blue bars, 1420RH; light red bars, 1420HH) or absence (blue bars, 1420RH; red bars, 1420HH) of DZG. The SI of normal SC-islets (1420RR, green bars) in the absence of DZG is shown as a reference. IS1 (differentiations 3–6): 1420RR, n =5; 1420RH, n =4; 1420HH, n =3. IS2 (differentiation 6 and 7): 1420RR, n =2; 1420RH, n =2; 1420HH, n =2. Data are presented as mean ± SD. * p <0.05
Praliciguat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/praliciguat/product/MedChemExpress
Average 94 stars, based on 1 article reviews
praliciguat - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
cas  (MedChemExpress)
91
MedChemExpress cas
Mature 1420RH SC-islets respond to <t>dorzagliatin.</t> For testing the effect of dorzagliatin, S7W2 IS1 SC-islets ( a , b , d , e ) and IS2 SC-islets ( c , f ) were used. SC-islets were perifused with KRB containing 2 mmol/l glucose (2G, minutes 1–14) followed by 11 mmol/l glucose (11G) or 20 mmol/l glucose (20G, minutes 15–44) with or without 25 µmol/l dorzagliatin (DZG). The flowthrough was assessed for insulin secretion every minute. ( a ) Insulin secretory response (SI) from S7W2 IS1 heterozygous 1420RH SC-islets (differentiations 4–6) when treated with 11G glucose in the presence (dashed blue line) or absence (solid blue line) of DZG. The response from normal SC-islets (1420RR, green line) in the absence of DZG is shown as a reference. 1420RR, n =3; 1420RH, n =3. Data are presented as mean ± SEM. ( b , c ) Insulin secretory response from S7W2 IS1 ( b ) and IS2 ( c ) heterozygous 1420RH and homozygous 1420HH SC-islets when treated with 20G glucose in the presence (dashed blue line, 1420RH; dashed red line, 1420HH) or absence (solid blue line, 1420RH; solid red line, 1420HH) of DZG. The response from normal SC-islets (1420RR, green line) in the absence of DZG is shown as a reference. IS1 (differentiations 3–6): 1420RR, n =5; 1420RH, n =4; 1420HH, n =3. IS2 (differentiation 6 and 7): 1420RR, n =2; 1420RH, n =2; 1420HH, n =2. Data are presented as mean ± SEM. ( d ) First-phase peak, first-phase (minutes 15–22) and second-phase (minutes 23–44) SI during d-GSIS using S7W2 IS1 heterozygous 1420RH SC-islets ( n =3) challenged with 11G in the presence (light blue bar) or absence (blue bar) of DZG. The SI of normal SC-islets (1420RR, n =3, green bar) in the absence of DZG is shown as a reference. Data are presented as mean ± SD. ( e , f ) First-phase peak, first-phase (minutes 15–22) and second-phase (minutes 23–44) SI during d-GSIS using S7W2 IS1 ( e ) and IS2 ( f ) heterozygous 1420RH and homozygous 1420HH SC-islets challenged with 20G in the presence (light blue bars, 1420RH; light red bars, 1420HH) or absence (blue bars, 1420RH; red bars, 1420HH) of DZG. The SI of normal SC-islets (1420RR, green bars) in the absence of DZG is shown as a reference. IS1 (differentiations 3–6): 1420RR, n =5; 1420RH, n =4; 1420HH, n =3. IS2 (differentiation 6 and 7): 1420RR, n =2; 1420RH, n =2; 1420HH, n =2. Data are presented as mean ± SD. * p <0.05
Cas, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cas/product/MedChemExpress
Average 91 stars, based on 1 article reviews
cas - by Bioz Stars, 2026-02
91/100 stars
  Buy from Supplier
substitution ds  (MedChemExpress)
93
MedChemExpress substitution ds
Mature 1420RH SC-islets respond to <t>dorzagliatin.</t> For testing the effect of dorzagliatin, S7W2 IS1 SC-islets ( a , b , d , e ) and IS2 SC-islets ( c , f ) were used. SC-islets were perifused with KRB containing 2 mmol/l glucose (2G, minutes 1–14) followed by 11 mmol/l glucose (11G) or 20 mmol/l glucose (20G, minutes 15–44) with or without 25 µmol/l dorzagliatin (DZG). The flowthrough was assessed for insulin secretion every minute. ( a ) Insulin secretory response (SI) from S7W2 IS1 heterozygous 1420RH SC-islets (differentiations 4–6) when treated with 11G glucose in the presence (dashed blue line) or absence (solid blue line) of DZG. The response from normal SC-islets (1420RR, green line) in the absence of DZG is shown as a reference. 1420RR, n =3; 1420RH, n =3. Data are presented as mean ± SEM. ( b , c ) Insulin secretory response from S7W2 IS1 ( b ) and IS2 ( c ) heterozygous 1420RH and homozygous 1420HH SC-islets when treated with 20G glucose in the presence (dashed blue line, 1420RH; dashed red line, 1420HH) or absence (solid blue line, 1420RH; solid red line, 1420HH) of DZG. The response from normal SC-islets (1420RR, green line) in the absence of DZG is shown as a reference. IS1 (differentiations 3–6): 1420RR, n =5; 1420RH, n =4; 1420HH, n =3. IS2 (differentiation 6 and 7): 1420RR, n =2; 1420RH, n =2; 1420HH, n =2. Data are presented as mean ± SEM. ( d ) First-phase peak, first-phase (minutes 15–22) and second-phase (minutes 23–44) SI during d-GSIS using S7W2 IS1 heterozygous 1420RH SC-islets ( n =3) challenged with 11G in the presence (light blue bar) or absence (blue bar) of DZG. The SI of normal SC-islets (1420RR, n =3, green bar) in the absence of DZG is shown as a reference. Data are presented as mean ± SD. ( e , f ) First-phase peak, first-phase (minutes 15–22) and second-phase (minutes 23–44) SI during d-GSIS using S7W2 IS1 ( e ) and IS2 ( f ) heterozygous 1420RH and homozygous 1420HH SC-islets challenged with 20G in the presence (light blue bars, 1420RH; light red bars, 1420HH) or absence (blue bars, 1420RH; red bars, 1420HH) of DZG. The SI of normal SC-islets (1420RR, green bars) in the absence of DZG is shown as a reference. IS1 (differentiations 3–6): 1420RR, n =5; 1420RH, n =4; 1420HH, n =3. IS2 (differentiation 6 and 7): 1420RR, n =2; 1420RH, n =2; 1420HH, n =2. Data are presented as mean ± SD. * p <0.05
Substitution Ds, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/substitution ds/product/MedChemExpress
Average 93 stars, based on 1 article reviews
substitution ds - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

Image Search Results


Mature 1420RH SC-islets respond to dorzagliatin. For testing the effect of dorzagliatin, S7W2 IS1 SC-islets ( a , b , d , e ) and IS2 SC-islets ( c , f ) were used. SC-islets were perifused with KRB containing 2 mmol/l glucose (2G, minutes 1–14) followed by 11 mmol/l glucose (11G) or 20 mmol/l glucose (20G, minutes 15–44) with or without 25 µmol/l dorzagliatin (DZG). The flowthrough was assessed for insulin secretion every minute. ( a ) Insulin secretory response (SI) from S7W2 IS1 heterozygous 1420RH SC-islets (differentiations 4–6) when treated with 11G glucose in the presence (dashed blue line) or absence (solid blue line) of DZG. The response from normal SC-islets (1420RR, green line) in the absence of DZG is shown as a reference. 1420RR, n =3; 1420RH, n =3. Data are presented as mean ± SEM. ( b , c ) Insulin secretory response from S7W2 IS1 ( b ) and IS2 ( c ) heterozygous 1420RH and homozygous 1420HH SC-islets when treated with 20G glucose in the presence (dashed blue line, 1420RH; dashed red line, 1420HH) or absence (solid blue line, 1420RH; solid red line, 1420HH) of DZG. The response from normal SC-islets (1420RR, green line) in the absence of DZG is shown as a reference. IS1 (differentiations 3–6): 1420RR, n =5; 1420RH, n =4; 1420HH, n =3. IS2 (differentiation 6 and 7): 1420RR, n =2; 1420RH, n =2; 1420HH, n =2. Data are presented as mean ± SEM. ( d ) First-phase peak, first-phase (minutes 15–22) and second-phase (minutes 23–44) SI during d-GSIS using S7W2 IS1 heterozygous 1420RH SC-islets ( n =3) challenged with 11G in the presence (light blue bar) or absence (blue bar) of DZG. The SI of normal SC-islets (1420RR, n =3, green bar) in the absence of DZG is shown as a reference. Data are presented as mean ± SD. ( e , f ) First-phase peak, first-phase (minutes 15–22) and second-phase (minutes 23–44) SI during d-GSIS using S7W2 IS1 ( e ) and IS2 ( f ) heterozygous 1420RH and homozygous 1420HH SC-islets challenged with 20G in the presence (light blue bars, 1420RH; light red bars, 1420HH) or absence (blue bars, 1420RH; red bars, 1420HH) of DZG. The SI of normal SC-islets (1420RR, green bars) in the absence of DZG is shown as a reference. IS1 (differentiations 3–6): 1420RR, n =5; 1420RH, n =4; 1420HH, n =3. IS2 (differentiation 6 and 7): 1420RR, n =2; 1420RH, n =2; 1420HH, n =2. Data are presented as mean ± SD. * p <0.05

Journal: Diabetologia

Article Title: Modelling the effects of human SUR1 R1420H variation on insulin secretory function using isogenic iPSC-derived pancreatic islets

doi: 10.1007/s00125-025-06605-1

Figure Lengend Snippet: Mature 1420RH SC-islets respond to dorzagliatin. For testing the effect of dorzagliatin, S7W2 IS1 SC-islets ( a , b , d , e ) and IS2 SC-islets ( c , f ) were used. SC-islets were perifused with KRB containing 2 mmol/l glucose (2G, minutes 1–14) followed by 11 mmol/l glucose (11G) or 20 mmol/l glucose (20G, minutes 15–44) with or without 25 µmol/l dorzagliatin (DZG). The flowthrough was assessed for insulin secretion every minute. ( a ) Insulin secretory response (SI) from S7W2 IS1 heterozygous 1420RH SC-islets (differentiations 4–6) when treated with 11G glucose in the presence (dashed blue line) or absence (solid blue line) of DZG. The response from normal SC-islets (1420RR, green line) in the absence of DZG is shown as a reference. 1420RR, n =3; 1420RH, n =3. Data are presented as mean ± SEM. ( b , c ) Insulin secretory response from S7W2 IS1 ( b ) and IS2 ( c ) heterozygous 1420RH and homozygous 1420HH SC-islets when treated with 20G glucose in the presence (dashed blue line, 1420RH; dashed red line, 1420HH) or absence (solid blue line, 1420RH; solid red line, 1420HH) of DZG. The response from normal SC-islets (1420RR, green line) in the absence of DZG is shown as a reference. IS1 (differentiations 3–6): 1420RR, n =5; 1420RH, n =4; 1420HH, n =3. IS2 (differentiation 6 and 7): 1420RR, n =2; 1420RH, n =2; 1420HH, n =2. Data are presented as mean ± SEM. ( d ) First-phase peak, first-phase (minutes 15–22) and second-phase (minutes 23–44) SI during d-GSIS using S7W2 IS1 heterozygous 1420RH SC-islets ( n =3) challenged with 11G in the presence (light blue bar) or absence (blue bar) of DZG. The SI of normal SC-islets (1420RR, n =3, green bar) in the absence of DZG is shown as a reference. Data are presented as mean ± SD. ( e , f ) First-phase peak, first-phase (minutes 15–22) and second-phase (minutes 23–44) SI during d-GSIS using S7W2 IS1 ( e ) and IS2 ( f ) heterozygous 1420RH and homozygous 1420HH SC-islets challenged with 20G in the presence (light blue bars, 1420RH; light red bars, 1420HH) or absence (blue bars, 1420RH; red bars, 1420HH) of DZG. The SI of normal SC-islets (1420RR, green bars) in the absence of DZG is shown as a reference. IS1 (differentiations 3–6): 1420RR, n =5; 1420RH, n =4; 1420HH, n =3. IS2 (differentiation 6 and 7): 1420RR, n =2; 1420RH, n =2; 1420HH, n =2. Data are presented as mean ± SD. * p <0.05

Article Snippet: Approximately 100 immature SC-islets and 70 mature SC-islets were first perifused with KRB containing 2 mmol/l glucose for equilibration (90 min) followed by KRB containing different glucose concentrations and/or drugs (diazoxide [catalogue no. S4030, Selleckchem], tolbutamide [catalogue no. T0891, Millipore Sigma] and dorzagliatin [catalogue no. HY-109030, MedChem Express]) as indicated in the figure legends at a flowrate of 100 μl/min.

Techniques: